CYTK Company Profile and Key Details

CYTK has shown sold momentum, gaining 3.21% over the past week and 28.89% over the past quarter, though year-to-date performance is up 33.33%. Short-term trend indicators are bearishly aligned (SMA20 -2.15%, SMA50 0.28%, SMA200 38.2%). The stock’s 14-day RSI is 49.42 (neutral), while the ATR of 2.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.53% below its high and over 113.99% above its low. Average 10-day trading volume of 1.52 million shares is below the 3-month average of 1.81 million, indicating normal recent market interest.

Cytokinetics, Incorporated has 119.66 million shares outstanding. The public float is 119.10 million shares, elevated short interest at 15.07% of float. This equals 13.83 million shares. The short ratio is 8.42 days. Institutional investors hold 118.77% of the float. Insiders own 0.69%. Blum Robert I holds 358.11 thousand shares, Cragg David has 138.70 thousand shares and Malik Fady Ibraham has 138.55 thousand shares. Over the past six months, insider transactions show net selling. They sold 199.40 thousand shares across 33 transactions.

Cytokinetics, Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$12.99. This means the shares are trading below this model’s fair value.

Cytokinetics, Incorporated (NASDAQ:CYTK) closed at $62.72 USD, gaining $0.52 (0.84%) from the previous close of $62.20. The stock is currently mid-range between its 52-week high and low $29.31 and $69.33. With a market capitalization of about $7.46 billion, Cytokinetics, Incorporated is classified as a mid-cap and shows lower-than-market volatility (beta ~0.59). Key stats such as the average daily volume over the past year has been around 1.87 million shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Cytokinetics, Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert I. Blum, the company employs approximately 498 people and listed since April 30, 2004. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.

Cytokinetics, Incorporated generated EPS of -$6.31 over the past year. Five-year average earnings growth is -20.02%. Wall Street analysts project EPS growth of 9.29% annually over the next five years. The latest quarter delivered EPS of -$2.55. The next quarter is forecast at -$1.55. Next year's EPS is expected at $8.00. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 20 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $120.00 to $41.00. The high target offers 91.33% upside. The low target suggests -34.63% downside. The mean target is $86.79. This offers 38.38% upside. Cytokinetics, Incorporated earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 60.38%. The prior quarter beat by -16.42%. Over the last six quarters, Apple has recorded several small beats. These include 28.43% in August 08, 2024.

Cytokinetics, Incorporated trades at a P/E ratio of -10.01, slightly below the S&P 500 average, with a price-to-sales ratio of 85.57 and a price-to-book ratio of -14.44 indicating negative book value, which may reflect financial stress. The P/FCF stands at -16.46, also below market averages.

Cytokinetics, Incorporated (NASDAQ:CYTK) shares are up 33.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cytokinetics, Incorporated trading at a premium to the broader market with a P/E of -10.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $74.93, suggesting 19.47% upside. Our AI forecast model points to short-term weakness (-6.52% over two weeks), a medium-term fall (-9.87% over three months), and a longer-term gain (9.3% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cytokinetics, Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.52%, with price expected at $58.63 by January 02, 2026, within a range of $56.60 to $60.56 3-Month Outlook: Projected fall of -9.87%, reaching $56.53 by March 19, 2026, with a range of $54.36 to $58.52. 1-Year Outlook: Projected gain of 9.3%, with price at $68.55 by December 18, 2026, within a range of $63.33 to $73.87.